Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

IMA910

Vaccine (Peptide vaccine) · Immune activation · developed by Immatics Biotechnologies GmbH

Phase 1/2 Most advanced trial (none active)
IMTX Developer
1 Registered trials

What is IMA910?

IMA910 is a synthetic peptide vaccine containing 13 tumor-associated peptides (TUMAPs), each representing a tumor-associated antigen specific for colorectal cancer. It is designed to elicit a cytotoxic T-lymphocyte response against colorectal tumors expressing these antigens. It is studied in colorectal carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Vaccine (Peptide vaccine)
Mechanism
Immune activation
Pathways
cytotoxic T-lymphocyte response
Therapy area
Oncology
Developer
Immatics Biotechnologies GmbH (IMTX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00785122 Phase 1/2 Colorectal Carcinoma Completed IMTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Colorectal Carcinoma

More from Immatics Biotechnologies GmbH

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the IMTX page.

Follow IMTX, the company behind IMA910

See IMTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IMTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.